Immunogen (IMGN) 12.17 $IMGN
Immunogen Down 17.8% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Mon May 12, 12:22PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 2 month, Immunogen has returned 17.81% as of today's recent price of $12.21.
Post Earnings Update: Immunogen Has Sunk 4.3% Lower in Past 2 Weeks (IMGN)
Comtex SmarTrend(R) - Mon May 12, 11:32AM CDT
Two weeks ago on April 25th, 2014 Immunogen (NASDAQ:IMGN) reported earnings and analysts, on average, expected a loss of $0.26 on sales of $13.3 million. The company actually reported a loss of $0.44 per share on sales of $6.9 million, missing EPS estimates by $0.18 and missing revenue estimates by $6.4 million. Shares of Immunogen have slipped from $12.39 to $11.86, representing a loss of 4.3%, since the company reported earnings 17 days ago.
Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Business Wire - Tue May 06, 10:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Shares of IMGN Down 19.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon May 05, 9:47AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 1 month, Immunogen has returned 19.19% as of today's recent price of $12.00.
In Line Q3 Loss at ImmunoGen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:40AM CDT
ImmunoGen (IMGN) reported third quarter fiscal 2014 loss of 29 cents per share at par with the Zacks Consensus Estimate.
Immunogen Has Returned 17.1% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Mon Apr 28, 9:10AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 1 month, Immunogen has returned 17.14% as of today's recent price of $12.31.
Rising R&D Expenses Drive ImmunoGen's Q3 Loss Significantly Higher
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 25, 11:33AM CDT
Antibody-drug conjugate developer ImmunoGen reported disappointing third-quarter earnings results before the opening bell this morning, delivering a decline in revenue, a considerably wider loss, and lowering its outlook for the year. For the...
Why ImmunoGen (IMGN) Stock Is Down Today
at The Street - Fri Apr 25, 11:31AM CDT
ImmunoGen (IMGN) stock is tumbling on Friday after the biotechnology company saw third-quarter losses gap wider than expected and as revenue fell short of analysts' estimates.
Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:39AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as its shares rose nearly 11% on the day.
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update a^'Quarterly Conference Call Today at 8:00 am ETa^'
Business Wire - Fri Apr 25, 5:30AM CDT
--Kadcyla(R) sales growing - launches in European Union starting.
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Biodel, HEC Pharm Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:30PM CDT
Biodel Inc. (BIOD) signed a research supply and technology development agreement with HEC Pharm for ultra-rapid-acting insulin aspart.
Companies With Upcoming Earnings Releases -- Research on Cerner, Ventas, NTT DOCOMO, and ImmunoGen
PR Newswire - Thu Apr 24, 7:00AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Cerner Corp. (NASDAQ: CERN), Ventas Inc. (NYSE: VTR), NTT DOCOMO Inc. (NYSE: DCM) and ImmunoGen Inc. (NASDAQ: IMGN). Full earnings notes on CERN, VTR, DCM and IMGN can be downloaded upon signing up at:
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
The Fool Looks Ahead
Rick Munarriz, The Motley Fool - Motley Fool - Sat Apr 19, 9:00AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday The market kicks off the new trading week after taking Friday off in a fury. It's earnings season, and the financial reports will...
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
Business Wire - Thu Apr 17, 3:20PM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2014. Management also will provide an update on the Company.
Immunogen Down 17.8% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Mon May 12, 12:22PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 2 month, Immunogen has returned 17.81% as of today's recent price of $12.21.
Post Earnings Update: Immunogen Has Sunk 4.3% Lower in Past 2 Weeks (IMGN)
Comtex SmarTrend(R) - Mon May 12, 11:32AM CDT
Two weeks ago on April 25th, 2014 Immunogen (NASDAQ:IMGN) reported earnings and analysts, on average, expected a loss of $0.26 on sales of $13.3 million. The company actually reported a loss of $0.44 per share on sales of $6.9 million, missing EPS estimates by $0.18 and missing revenue estimates by $6.4 million. Shares of Immunogen have slipped from $12.39 to $11.86, representing a loss of 4.3%, since the company reported earnings 17 days ago.
Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Business Wire - Tue May 06, 10:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Shares of IMGN Down 19.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon May 05, 9:47AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 1 month, Immunogen has returned 19.19% as of today's recent price of $12.00.
In Line Q3 Loss at ImmunoGen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:40AM CDT
ImmunoGen (IMGN) reported third quarter fiscal 2014 loss of 29 cents per share at par with the Zacks Consensus Estimate.
Immunogen Has Returned 17.1% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Mon Apr 28, 9:10AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on March 28th, 2014 at $14.85. In approximately 1 month, Immunogen has returned 17.14% as of today's recent price of $12.31.
Rising R&D Expenses Drive ImmunoGen's Q3 Loss Significantly Higher
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 25, 11:33AM CDT
Antibody-drug conjugate developer ImmunoGen reported disappointing third-quarter earnings results before the opening bell this morning, delivering a decline in revenue, a considerably wider loss, and lowering its outlook for the year. For the...
Why ImmunoGen (IMGN) Stock Is Down Today
at The Street - Fri Apr 25, 11:31AM CDT
ImmunoGen (IMGN) stock is tumbling on Friday after the biotechnology company saw third-quarter losses gap wider than expected and as revenue fell short of analysts' estimates.
Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:39AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as its shares rose nearly 11% on the day.
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update a^'Quarterly Conference Call Today at 8:00 am ETa^'
Business Wire - Fri Apr 25, 5:30AM CDT
--Kadcyla(R) sales growing - launches in European Union starting.
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Biodel, HEC Pharm Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:30PM CDT
Biodel Inc. (BIOD) signed a research supply and technology development agreement with HEC Pharm for ultra-rapid-acting insulin aspart.
Companies With Upcoming Earnings Releases -- Research on Cerner, Ventas, NTT DOCOMO, and ImmunoGen
PR Newswire - Thu Apr 24, 7:00AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Cerner Corp. (NASDAQ: CERN), Ventas Inc. (NYSE: VTR), NTT DOCOMO Inc. (NYSE: DCM) and ImmunoGen Inc. (NASDAQ: IMGN). Full earnings notes on CERN, VTR, DCM and IMGN can be downloaded upon signing up at:
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
The Fool Looks Ahead
Rick Munarriz, The Motley Fool - Motley Fool - Sat Apr 19, 9:00AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday The market kicks off the new trading week after taking Friday off in a fury. It's earnings season, and the financial reports will...
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
Business Wire - Thu Apr 17, 3:20PM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2014. Management also will provide an update on the Company.
